Fallopian Tube Cancer Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)
Conditions: Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer Intervention: Drug: Mirvetuximab soravtansine Sponsors: ImmunoGen, Inc.; IQVIA Biotech Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 13, 2021 Category: Research Source Type: clinical trials
Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Clear Cell Adenocarcinoma; Recurrent Ovarian Clear Cell Adenocarcinoma; Recurrent Platinum-Resistant Fallopian Tube Carcinoma; Recurrent Platinum-Resistant Ovarian Carcinoma; Recurrent Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Prima ry Peritoneal Clear Cell Adenocarcinoma Interventions: Biological: Etigilimab; Biological: Nivolumab Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2021 Category: Research Source Type: clinical trials
